Seeking Alpha

Par Pharmaceutical (PRX +0.2%) says that its operating subsidiary has begun shipping 5 mg and 10...

Par Pharmaceutical (PRX +0.2%) says that its operating subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets. Rizatriptan benzoate is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age. Annual U.S. sales of the drug total approximately $653M.
Comments (1)
  • Boomerdude
    , contributor
    Comments (87) | Send Message
     
    Rizatriptan is a generic drug of the "triptan" class, marketed by Merck as Maxalt. This is not the first generic triptan on the market (sumatriptan is), but it is a widely used and commonly effective treatment. Par is privately held.
    2 Jan 2013, 12:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|